Product Details for NDA 210875
KYNMOBI (APOMORPHINE HYDROCHLORIDE)
10MG
Marketing Status: Discontinued
15MG
Marketing Status: Discontinued
20MG
Marketing Status: Discontinued
25MG
Marketing Status: Discontinued
30MG
Marketing Status: Discontinued
10MG
Marketing Status: Discontinued
Active Ingredient: APOMORPHINE HYDROCHLORIDE
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 10MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 001
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
KYNMOBI (APOMORPHINE HYDROCHLORIDE)
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 10MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 001
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
15MG
Marketing Status: Discontinued
Active Ingredient: APOMORPHINE HYDROCHLORIDE
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 15MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 002
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
KYNMOBI (APOMORPHINE HYDROCHLORIDE)
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 15MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 002
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
20MG
Marketing Status: Discontinued
Active Ingredient: APOMORPHINE HYDROCHLORIDE
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 20MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 003
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
KYNMOBI (APOMORPHINE HYDROCHLORIDE)
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 20MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 003
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
25MG
Marketing Status: Discontinued
Active Ingredient: APOMORPHINE HYDROCHLORIDE
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 25MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 004
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
KYNMOBI (APOMORPHINE HYDROCHLORIDE)
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 25MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 004
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
30MG
Marketing Status: Discontinued
Active Ingredient: APOMORPHINE HYDROCHLORIDE
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 30MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 005
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information
Proprietary Name: KYNMOBI
Dosage Form; Route of Administration: FILM; SUBLINGUAL
Strength: 30MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code:
Application Number: N210875
Product Number: 005
Approval Date: May 21, 2020
Applicant Holder Full Name: SUMITOMO PHARMA AMERICA INC
Marketing Status: Discontinued
Patent and Exclusivity Information